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Epithelial ovarian cancer is the leading cause of death among female genital malignancies. Reduced expression of the cell adhesion
molecule E-cadherin was previously shown to be associated with adverse prognostic features. The role of the E-cadherin repressor
Snail in ovarian cancer progression remains to be elucidated. We analysed formalin-fixed and paraffin-embedded specimens of 48
primary ovarian tumours and corresponding metastases for expression of E-cadherin and Snail by immunohistochemistry. We found
a significant correlation between E-cadherin expression in primary cancers and their corresponding metastases (Po0.001). This
correlation was found for Snail expression as well (Po0.001). There was a significant (P¼0.008) association of reduced E-cadherin
expression in primary ovarian cancer with shorter overall survival. Similarly, Snail expression in corresponding metastases (P¼0.047)
was associated with reduced overall survival of the patients. Additionally, the group of patients showing reduced E-cadherin and
increased Snail immunoreactivity in primary tumours and corresponding metastases, respectively, had a significantly higher risk of
death (P¼0.002 and 0.022, respectively) when compared to the patient group with the reference expression profile E-cadherin
positive and Snail negative. Taken together, the results of our study show that the E-cadherin repressor Snail is associated with lower
overall survival of ovarian cancer patients.
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Epithelial ovarian cancer is the second most common gynaecolo-
gical cancer and the leading cause of death among female genital
malignancies in the developed world (Parkin et al, 2005;
Sankaranarayanan and Ferlay, 2005). More than two-thirds of
patients with ovarian cancer are diagnosed with advanced-stage
disease, because ovarian cancer is often asymptomatic in its early
stages (Ozols, 2005). The degree of peritoneal dissemination is
related to the poor prognosis in patients with advanced-stage
ovarian cancer. The molecular mechanisms that allow ovarian
cancer cells to detach from the primary tumour, invade the
peritoneal surfaces, and regrow at this site are not yet well
understood. Nevertheless, it is known that epithelial–mesenchy-
mal transition (EMT) is an important mechanism during early
steps of tumour progression where tumour cells disseminate from
the primary tumour (Thiery and Chopin, 1999; Thiery, 2002, 2003;
Gotzmann et al, 2004). Predominantly, EMT is a key process in
normal embryonic development by which epithelial cells acquire a
fibroblastoid morphology, accompanied by the loss of epithelial
and gain of mesenchymal markers (Hay, 1995; Thiery and Chopin,
1999; Thiery, 2003). The process of acquisition of the invasive
phenotype by epithelial tumours can be regarded as a pathologic
version of the EMT of embryogenesis.
Expression of the homophilic Ca
2þ-dependent cell adhesion
molecule E-cadherin is lost during EMT. As a key regulator of the
differentiated epithelial phenotype, E-cadherin plays a critical role
in the suppression of tumour invasion, and its function is required
for the maintenance of stable adherens junctions and epithelial cell
polarity (Takeichi, 1991; Perez-Moreno et al, 2003). Occurrence of
altered E-cadherin expression has been correlated with dediffer-
entiation, increased risk of local invasion and metastatic disease,
and recurrence and poor prognosis in a variety of carcinomas, for
example, breast, uterine cervix, or gastric carcinomas (Moll et al,
1993; Fujimoto et al, 1997; Jawhari et al, 1997; Jeffers et al, 1997;
Huiping et al, 2001). Previous studies have shown that reduced
expression of E-cadherin in ovarian cancer is associated with the
invasive phenotype, advancing tumour stage, lower 5-year survival
rate, and poor recurrence-free survival (Faleiro-Rodrigues et al,
2004; Imai et al, 2004; Marques et al, 2004; Voutilainen et al, 2006)
but not much is known about the underlying mechanisms of
E-cadherin downregulation.
A regulator of E-cadherin expression is the transcription factor
Snail, a member of the Snail superfamily of zinc-finger transcrip-
tion factors, which was first identified in Drosophila melanogaster
(Grau et al, 1984; Nieto, 2002). Snail mediates events in mesoderm,
neuroectoderm, and other organ development in the embryo but is
also an important effector of the process of invasiveness and
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stumorigenecity (Hemavathy et al, 2000). Snail is considered as a
key regulator of EMT as it represses the transcription of
E-cadherin by binding to E-box elements found in the proximal
E-cadherin promoter, thereby triggering a complete EMT with the
acquisition of invasive and tumorigenic properties (Batlle et al,
2000; Cano et al, 2000; Peinado et al, 2004; De Craene et al,
2005). In humans, Snail mRNA expression has been detected in
biopsies or resected tissue samples from patients with breast
cancer (Blanco et al, 2002), gastric cancer (Rosivatz et al, 2002),
hepatocellular carcinomas (Jiao et al, 2002), oral squamous cell
carcinoma (Yokoyama et al, 2001), and ovarian carcinoma
(Elloul et al, 2006). Because Snail is significantly regulated at the
protein level, we decided to analyse Snail immunoreactivity in
ovarian cancer. Our recently established Snail-specific antibody
allows a direct cellular comparison between E-cadherin down-
regulation and endogenous nuclear Snail expression at the protein
level in cancer tissues (Rosivatz et al, 2006; Blechschmidt et al,
2007).
The aim of our study was to elucidate the role of the
transcription factor Snail in E-cadherin downregulation and
cancer progression in ovarian carcinomas.
MATERIALS AND METHODS
Tissue samples
A total of 51 patients who had undergone primary surgery for
newly diagnosed advanced-stage (FIGO IIIC and IV) ovarian
cancer between 1998 and 2001 at the University Hospital of the
Technical University of Munich were eligible for this retrospective
analysis. Exclusion criteria were a second malignancy or
chemotherapy or radiotherapy within the last 6 months prior to
surgery. Follow-up data were available for all patients, with a
median follow-up time of 55 months.
Formalin-fixed and paraffin-embedded specimens of the pri-
mary ovarian tumours and corresponding metastases were
immunohistochemically analysed for expression of E-cadherin
and Snail. In 47 cases, specimens of the primary tumour as well as
the corresponding metastases were analysed, in one case only the
primary tumour was available, and in three cases only specimens
of metastases were analysed. Metastases were located in the
peritoneum (n¼17), omentum (n¼25), distant lymph nodes
(n¼6), and uterus (n¼2).
Immunohistochemistry
Sections (4mm) of formalin-fixed and paraffin-embedded material
were analysed. For detection of E-cadherin- and Snail-specific
immunoreactivity, sections were treated as follows: after standard
pressure-cooker-based antigen retrieval with citric acid (pH 6.0)
pretreatment, sections were incubated with either H2O2 (for
E-cadherin) or normal goat serum (for Snail).
The sections were incubated with either a monoclonal anti-
E-cadherin antibody (1:1500) (clone 36; Transduction Laboratories,
Lexington, KY, USA) at room temperature for 1h or a monoclonal
anti-Snail antibody (1:20) (hybridoma supernatant Sn9H2;
Rosivatz et al, 2006) at room temperature for 2h. Both antibodies
were detected using the avidin–biotin complex peroxidase
method (ABC Elite Kit; Vector, Burlingame, CA, USA). Final
staining was developed with the Sigma FAST DAB peroxidase
substrate kit (Sigma, Deisenhofen, Germany). Haemalaun was
used for counterstaining. For the analysis of E-cadherin immuno-
reactivity, adjacent endometrium, intestinal mucosa, or non-
tumorous ovarian surface epithelium was used as an endogenous
positive control. Sections of archival placental tissue were used
as a positive control for Snail immunoreactivity (Rosivatz et al,
2006).
Immunohistochemical evaluation
Expression of E-cadherin and Snail was assessed using a
semiquantitative scoring system, ranging from 0, 1þ,2þ,a n d3þ.
E-cadherin expression was scored as follows:
  0, no immunoreactivity or immunoreactivity of o10% of
tumour cells
  1þ, low-intensity immunoreactivity of X10% of tumour cells
  2þ, medium-intensity immunoreactivity of X10% of tumour
cells
  3þ, high-intensity immunoreactivity of X10% of tumour cells
All cases were summarised into two groups, showing preserved
E-cadherin expression (score 3þ) or reduced E-cadherin expres-
sion (scores 0, 1þ, and 2þ).
Snail expression was evaluated as following:
  0, no immunoreactivity or immunoreactivity of o1% of tumour
cells
  1þ, immunoreactivity of 1% of tumour cells
  2þ, immunoreactivity of 2–5% of tumour cells
  3þ, immunoreactivity of 45% of tumour cells
Snail staining was graded as positive only when nuclear staining
was detectable.
All cases were summarised into two groups, negative for Snail
expression (score 0) or positive for Snail expression (scores 1þ,
2þ, and 3þ).
Statistical analysis
Continuous variables are reported as median with range, and
categorical data are expressed as frequencies and percentages.
w
2-test and if appropriate Fisher Exact test were applied to test for
bivariate associations of categorical parameters. Logistic regres-
sion was used to perform multivariate investigations of binary-
response variables. Analysis of survival times was performed using
the method of Kaplan–Meier, and comparison of survival between
patient subgroups was done by Log-rank test and Cox proportional
hazard regression. Hazard ratios and median survival were
reported with 95% confidence intervals. All tests were performed
two-tailed at a 5% level of significance. Bonferroni adjustment of
a-error rate was considered in case of multiple comparisons, in
particular performing subgroup analysis. Analyses were conducted
using SPSS version 14.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
A total of 48 specimens of primary tumours and 50 specimens of
metastases of ovarian carcinomas were examined for E-cadherin
and Snail immunoreactivity, of which 47 cases were matched pairs
of primary tumours and their corresponding metastases (Figure 1).
A summary of the clinicopathological characteristics of the
patients is given in Table 1.
E-cadherin expression in primary and metastatic ovarian
cancer
E-cadherin expression was preserved (score 3þ) in 75% of
primary ovarian cancers and 78% of the corresponding metastases.
A reduced E-cadherin immunoreactivity (score 0, 1þ, and 2þ)
was found in 25% of primary tumours and 22% of metastases
(Table 2A).
There was a significant correlation between E-cadherin expres-
sion in ovarian cancers and their corresponding metastases
(Po0.001). Out of 35 primary tumours with preserved E-cadherin
expression, 33 (94.3%) showed preserved expression in the
corresponding metastases. Out of 12 primary tumours with
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sreduced E-cadherin expression, 8 (66.7%) showed reduced
expression in the corresponding metastases (Table 3). There was
no difference in E-cadherin expression in various metastatic
locations.
No association was found between E-cadherin immunoreactivity
and clinicopathological factors including patient age, tumour
grade, histological subtype, and FIGO stage in primary ovarian
cancers, nor in the corresponding metastases. These results
were confirmed by multivariate analysis considering E-cadherin
immunoreactivity in primary cancers and metastases, respectively,
and TNM status, tumour grade, histological subtype, and FIGO
stage. No statistical significance was found for multivariate
analysis as well.
Snail expression in primary and metastatic ovarian cancer
Expression of Snail (score 1þ,2 þ, and 3þ) was detected in
37.5% of primary ovarian cancers and in 52% of corresponding
metastases (Table 2B). There was a significant correlation between
Snail expression in ovarian cancers and their corresponding
metastases (Po0.001). Out of 17 primary tumours with positive
Snail expression, 16 (94.1%) showed Snail expression in the
corresponding metastases. Out of 30 primary tumours with
negative Snail immunoreactivity, 21 (70.0%) were negative for
Snail in the corresponding metastases (Table 3). There was no
difference in Snail expression in various metastatic locations. No
association was found between Snail expression and clinicopatho-
logical factors including patient age, tumour grade, histological
subtype, and FIGO stage in primary ovarian cancers nor in the
corresponding metastases. These results were confirmed by
multivariate analysis considering Snail immunoreactivity in
Table 1 Clinicopathological characteristics of the patients (n¼51)
Characteristic n %
Age, years
Median 63
Range 29–82
Histological grade
13 6
21 1 2 2
33 7 7 2
FIGO stage
III 39 76
IV 12 24
TNM staging
T
13 6
22 4
34 6 9 0
N
06 1 2
12 2 4 3
x2 3 4 5
M
03 8 7 4
11 1 2 2
x2 4
Histological type
Serous 39 76
Endometrioid 5 10
Others
a 71 4
End state
Dead 31 61
Alive 20 39
aIncludes three mucinous, two Muellerian, one Brenner, and one clear cell.
Table 2A E-cadherin expression in primary ovarian cancer and
corresponding metastases
Primary tumours (n¼48)
a Metastases (n¼50)
a
E-cadherin Score (n)( % ) ( n)( % )
Reduced 12 25.0 11 22.0
0 1 2.1 1 2.0
1+ 2 4.2 1 2.0
2+ 9 18.7 9 18.0
Preserved 3+ 36 75.0 39 78.0
aFor n¼47 cases, matched pairs of primary tumours and their corresponding
metastases were available for analysis. Reduced, reduced E-cadherin expression
defined by scores of 0, 1+, and 2+. Preserved, preserved E-cadherin expression
defined by a score of 3+. n, number of patients. The main categories of ‘reduced’
and ‘preserved’ (as compared to the subcategories of reduced expression) are shown
in bold.
E-cadherin
PT
MET
PT
MET
Snail
Figure 1 (A, B) Consecutive immunostainings for E-cadherin and Snail
of two ovarian cancer cases showing the primary tumours and the
corresponding metastases. (A) An ovarian cancer case showing reduced
E-cadherin immunostaining in the primary tumour (1þ), while E-cadherin
immunoreactivity is preserved in the corresponding metastasis (3þ). Snail
immunoreactivity is positive (3þ) for both, primary tumour and metastasis
(immunoperoxidase staining,  200). (B) An ovarian cancer case showing
preserved E-cadherin immunostaining (3þ) in primary tumour and
corresponding metastasis. Snail immunoreactivity is negative (0) in the
primary tumour, whereas it is positive (1þ) in the corresponding
metastasis. Note that tumour-associated stromal cells also show nuclear
staining for Snail (indicated by arrowheads) (immunoperoxidase staining,
 200). PT, primary tumour; MET, corresponding metastasis.
Snail in ovarian cancer
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sprimary cancers and metastases, respectively, and TNM status,
tumour grade, histological subtype, and FIGO stage. No statistical
significance was found for multivariate analysis as well.
There was no statistically significant correlation between E-
cadherin and Snail expression, neither in primary ovarian cancers
nor in their metastases. Out of 36 primary tumours with preserved
E-cadherin expression, 13 (36.1%) showed positive Snail and 23
(63.9%) negative Snail immunoreactivity (P¼0.743). Out of 39
metastases with preserved E-cadherin expression, 21 (53.8%)
showed positive Snail and 18 (46.2%) negative Snail immuno-
reactivity (P¼0.623).
E-cadherin and Snail expression and overall survival
There were significant differences in patients’ overall survival with
regard to E-cadherin expression in primary ovarian cancer
(P(log-rank)¼0.008; significant according to the adjusted significance
level) (Figure 2). Patients with a reduced E-cadherin expression
(n¼12) had a median overall survival of 17.9 months (95% CI:
5.8–30.0) compared to 48.8 months (95% CI: 24.0–73.6) in
patients with preserved E-cadherin expression (n¼36). The
corresponding hazard ratio was 2.82 (95% CI: 1.3–6.3). In
metastases, no significant differences were found in overall
survival when examining E-cadherin expression.
There was a borderline significant difference in the overall
survival of patients with positive Snail expression in metastases of
ovarian cancer compared to patients with negative Snail expres-
sion (P(log-rank)¼0.047) (Figure 3), whereas these differences were
not found in primary tumours. Patients with positive Snail
expression in their metastases (n¼26) had a lower median overall
survival of 17.9 months (95% CI: 12.2–23.7) with a hazard ratio of
2.10 (95% CI: 1.0–4.4). The median overall survival of patients
with Snail negative metastases (n¼24) has not yet been reached at
55 months of median follow-up time.
To analyse the patients’ overall survival with regard to different
combinations of E-cadherin and Snail expression profiles, we
divided the patients into four different groups, which are shown
in Tables 4A and B. The comparison of survival between the
different groups was done by multivariate Cox proportional hazard
regression adjusted for patient age. Since normal non-cancerous
epithelial tissue is characterised by preserved E-cadherin and
negative Snail expression, this expression profile served as a
reference standard. When analysing the protein expression profile
in primary ovarian tumours with regard to patient survival, we
found that only patients with the expression profile ‘E-cadherin
reduced and Snail positive’ showed a significantly (P¼0.002;
significant according to the adjusted significance level) higher risk
for the occurrence of death with a hazard ratio of 5.91 (95% CI:
1.9–18.0) when compared to the reference group (Table 4A). In
case of the corresponding metastases, a significantly (P¼0.025)
higher risk for the occurrence of death was seen in patients
with the same expression profile of ‘E-cadherin reduced and
Snail positive’ with a hazard ratio of 4.26 (95% CI: 1.2–15.2)
when compared to the reference group (Table 4B). Taken together,
a total of eight patients showed this profile of reduced E-cadherin
and positive Snail expression in either the primary tumour (n¼5)
or metastases (n¼5). (Two of these patients showed this profile
in both their primary tumor and metastases.) Out of these
eight patients, five (62.5%) were serous carcinomas, two (25%)
endometrioid, and one (12.5%) mucinous carcinoma. This
distribution of histological subtypes reflects their statistical
frequency in the study population (see Table 1).
DISCUSSION
In the current study, we analysed the active, that is, nuclear-
localised, Snail protein and its target E-cadherin by immunohisto-
chemistry in a series of primary ovarian carcinomas and their
Table 2B Snail expression in primary ovarian cancer and corresponding
metastases
Primary tumours (n¼48)
a Metastases (n¼50)
a
Snail Score (n)( % ) ( n)( % )
Negative 0 30 62.5 24 48.0
Positive 18 37.5 26 52.0
1+ 11 22.9 17 34.0
2+ 4 8.3 6 12.0
3+ 3 6.3 3 6.0
aFor n¼47 cases, matched pairs of primary tumours and their corresponding
metastases were available for analysis. Negative, no expression of Snail defined by a
score of 0. Positive, positive Snail expression defined by scores of 1+, 2+, and 3+. n,
number of patients. The main categories of ‘negative’ and ‘positive’ (as compared to
the subcategories of positive expression) are shown in bold.
Table 3 Correlation of E-cadherin and Snail expression in primary
ovarian cancer compared to the corresponding metastases
a
E-cadherin (n) Snail (n)
Primary positive 35 17
Primary negative 12 30
Primary positive, metastasis positive 33 (94.3% of n¼35) 16 (94.1% of n¼17)
Primary positive, metastasis negative 2 (5.7% of n¼35) 1 (5.9% of n¼17)
Primary negative, metastasis negative 8 (66.7% of n¼12) 21 (70.0% of n¼30)
Primary negative, metastasis positive 4 (33.3% of n¼12) 9 (30.0% of n¼30)
an¼47 cases for which both the primary tumours and their corresponding
metastases were available. Primary, primary ovarian cancer. Metastasis, corresponding
metastases of primary ovarian cancers. Positive, preserved immunoreactivity for
E-cadherin (3+) or Snail positive (1+, 2+, and 3+). Negative, reduced
immunoreactivity for E-cadherin (0, 1+, and 2+) or Snail negative (0).
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Figure 2 Kaplan–Meier survival curve for ovarian carcinoma patients
according to E-cadherin immunoreactivity in primary ovarian cancers.
Discontinuous line represents preserved E-cadherin immunoreactivity
(3þ). Continuous line represents reduced E-cadherin immunoreactivity
(2þ,1þ, and 0). Patients with reduced E-cadherin immunoreactivity had
a significantly shorter overall survival (P¼0.008).
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scorresponding metastases. The results show a significant associa-
tion between reduced E-cadherin expression in primary ovarian
cancer and shorter overall survival of the patients. Similarly,
positive Snail expression in the corresponding metastases was
correlated with reduced overall survival. Interestingly, for both
E-cadherin and Snail, we observed no significant difference in
expression between primary tumours and their corresponding
metastases.
The cell adhesion molecule E-cadherin has already been
described to be involved in tumour dedifferentiation and poor
recurrence-free survival in ovarian cancer (Imai et al, 2004;
Voutilainen et al, 2006). We showed that reduced E-cadherin
immunoreactivity in primary ovarian tumours was significantly
(P¼0.008) associated with shorter overall survival.
A key regulator of E-cadherin expression is the zinc-finger
transcription factor Snail, a master molecule of EMT (Cano et al,
2000). Up to now, more than 2000 cases from at least nine different
tumour types reported in more than 21 studies have been analysed
for Snail expression, including carcinomas from breast, stomach,
colon, liver, ovary, oesophagus, head and neck, and endometrium,
and synovial sarcomas (Becker et al, 2007). Elloul et al (2006)
recently analysed the expression of E-cadherin and its transcrip-
tional regulators in ovarian cancer. They evaluated the expression
of the repressors Snail, Slug, and SIP1 in fresh non-fixed material
of ovarian primary carcinomas, solid metastases, and malignant
peritoneal and pleural effusions by reverse transcription (RT)-PCR
and western blot. The authors reported positive Snail expression in
the majority of the analysed tumour specimens. Snail mRNA
expression was detected in 93% (38/41) primary tumours, 93% (14/
15) metastases, and 87% (68/78) effusions. Snail protein expression
determined by Western blot analysis was found in 100% (30/30)
primary tumours, 100% (10/10) metastases, and 97% (72/74)
effusions. The authors found that mean expression levels of Snail
protein were lower in effusions, with expression of 17% of control
levels in effusions compared to 118% in primary tumours and
127% in metastases (Elloul et al, 2006). These discrepancies
between Snail mRNA and protein expression levels may partly be
explained by potential posttranslational regulation mechanisms.
Besides being tightly regulated at the transcriptional level, Snail’s
Kaplan–Meier curve
100
80
60
40
20
C
u
m
u
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
 
(
%
)
0
01 2 2 4
Survival (months)
36 48 60
Snail negative (n=24)
Snail positive (n=26)
P=0.047
Figure 3 Kaplan–Meier survival curve for ovarian carcinoma patients according to Snail immunoreactivity in metastases of ovarian cancer. Discontinuous
line represents negative Snail immunoreactivity (0). Continuous line represents positive Snail immunoreactivity (1þ,2þ, and 3þ). Patients with positive
Snail immunoreactivity had a significantly shorter overall survival (P¼0.047).
Table 4A Comparison of survival in patient groups with different
expression profiles of E-cadherin and Snail in primary ovarian cancer using
multivariate Cox proportional hazard regression adjusted for patient age
95% CI for HR
Primary ovarian cancer (n¼48) P HR Lower Upper
E-cadherin+/Snail  (n¼23)
a 1.00
E-cadherin+/Snail+ (n¼13) 0.590 1.28 0.521 3.150
E-cadherin /Snail  (n¼7) 0.165 2.13 0.733 6.191
E-cadherin /Snail+ (n¼5) 0.002
# 5.91 1.973 18.036
Age (years) 0.890 1.01 0.973 1.032
CI¼confidence interval; HR¼hazard ratio for the occurrence of death;
+¼preserved immunoreactivity for E-cadherin (3+) or Snail positive (1+, 2+, and
3+);  ¼reduced immunoreactivity for E-cadherin (0, 1+, and 2+) or Snail negative
(0).
aWas set as the reference group.
#Significant according to the adjusted
significance level. n, number of patients. Bold value signifies P-value o0.05.
Table 4B Comparison of survival in patient groups with different
expression profiles of E-cadherin and Snail in metastases of ovarian cancer
using multivariate Cox proportional hazard regression adjusted for patient
age
95% CI for HR
Metastases of ovarian cancer (n¼50) P HR Lower Upper
E-cadherin+/Snail  (n¼18)
a 1.00
E-cadherin+/Snail+ (n¼21) 0.069 2.35 0.936 5.884
E-cadherin /Snail  (n¼6) 0.313 1.90 0.547 6.601
E-cadherin /Snail+ (n¼5) 0.025
# 4.26 1.198 15.159
Age (years) 0.692 1.01 0.977 1.036
CI¼confidence interval; HR¼hazard ratio for the occurrence of death;
+¼preserved immunoreactivity for E-cadherin (3+) or Snail positive (1+, 2+, and
3+);  ¼reduced immunoreactivity for E-cadherin (0, 1+, and 2+) or Snail negative
(0).
aWas set as the reference group. n, number of patients. Significant according to
the adjusted significant level. Bold value signifies P-value o0.05.
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sactivity is also influenced by its subcellular localisation. In ovarian
tumour cells derived from effusions, Elloul et al (2006) found that
Snail protein was exclusively localised in the cytoplasm, which may
reflect an inactive form of the protein (Dominguez et al, 2003).
Snail can cycle between the nucleus and the cytosol by virtue of a
nuclear export sequence. At least two kinases, glycogen synthase
kinase-3b and p21-activated kinase-1, are known to govern Snail’s
localisation (Dominguez et al, 2003; Zhou et al, 2004; Yang et al,
2005). In addition, the zinc-finger transporter LIV-1 seems to be
involved in this level of regulation, as shown for zebrafish
(Yamashita et al, 2004). The complexity of Snail’s functional
activation makes clear that it is a shortcoming of Western blot
analysis that only total protein expression is reflected, which does
not necessarily correlate to the amount of active Snail.
In the current study, we analysed the expression of nuclear-
localised, active Snail. We found that 37.5% of the primary
tumours and 52% of the corresponding metastases showed a
positive nuclear staining for Snail. In addition to Snail-positive
carcinoma cells, we also found tumour-associated stromal cells
showing a positive immunoreactivity for Snail. Snail-positive
stromal cells have been described previously by us (Blechschmidt
et al, 2007) and by Franci et al (2006) in endometrial and colon
cancer, respectively. This raises the question whether these Snail-
positive stromal cells represent former tumour cells that have
undergone mesenchymal transition. On the other hand, a de novo
expression of Snail in tumoral stroma might suggest a key role for
stromal cells in promoting tumour progression. The role of Snail
in tumour-associated stromal cells needs to be established in
additional studies.
We found a significant correlation between Snail expression in
primary ovarian tumours and their corresponding metastases
(Po0.001). Cases (94.1%) with a positive Snail immunoreactivity
in primary tumours were also Snail positive in the corresponding
metastases. On the other hand, 70% of cases with Snail-negative
primary tumours were also Snail negative in the corresponding
metastases, yet 30% showed a positive Snail immunoreactivity. In
previous studies, it was shown that Snail not only induces tumour
invasion but also blocks the cell cycle and confers resistance to cell
death (Vega et al, 2004). Our results indicate that these or other,
yet unknown, features of Snail might be of special importance for
the establishment or maintenance of metastases at the new
invasion site in ovarian cancer, possibly leading to preserved
Snail expression. Additionally, we demonstrated that positive Snail
immunoreactivity in metastases of ovarian cancer was significantly
associated with a lower overall survival of the patients. No
association was found between Snail expression in primary ovarian
cancer and survival.
There was no correlation between Snail immunoreactivity and
other clinicopathological parameters, including patient age,
tumour subtype, or grade of differentiation. The last might be
due to the small numbers of low-grade and low-stage cases as
discussed above. In the current study, there was no correlation
between Snail upregulation and E-cadherin downregulation,
neither in primary tumours nor in corresponding metastases.
We found coexpression of E-cadherin and Snail in 36.1% of
primary tumours and in 53.8% of metastases. These results are in
accordance with previous studies on endometrial and colon cancer
(Franci et al, 2006; Blechschmidt et al, 2007), although it is not yet
understood why Snail expression does not lead to E-cadherin
downregulation in these cases.
We also asked whether specific combinations of E-cadherin and
Snail protein expression had a prognostic value. We found that a
profile of reduced E-cadherin expression and nuclear Snail
expression was associated with a significantly increased risk of
death. Patients showing an ‘E-cadherin reduced and Snail positive’
profile, in either the primary tumours or corresponding meta-
stases, respectively, had a 6-fold and 4.2-fold increased risk of
death (P¼0.002 and 0.022, respectively) when compared to the
patient group with a ‘normal epithelial’ expression profile of
‘E-cadherin positive and Snail negative’.
Additionally, patients with a profile of preserved E-cadherin and
positive Snail expression in metastases were at an increased risk of
death (P¼0.077), although this association was not statistically
significant. Taken together, these observations indicate that Snail
might be an independent prognostic factor for clinical outcome in
ovarian cancer. Snail may be important for the establishment
and maintenance of metastases in ovarian cancer, while loss of
E-cadherin expression might be crucial in primary tumours, for
example, for tumour invasion, both leading to an adverse clinical
outcome for ovarian cancer patients.
This is the first study in which the subcellular expression of the
E-cadherin repressor Snail has been analysed in a series of ovarian
carcinomas. Our findings, although derived from a limited number
of patients, form an important basis for future prospective studies.
In conclusion, the results of our study show that Snail is associated
with lower overall survival of ovarian cancer patients and provide
new evidence for a role of Snail as a prognostic factor for adverse
clinical outcome in ovarian cancer.
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